SLU-PP-915 vs SLU-PP-332: compare these preclinical ERR agonists on potency, pharmacokinetics, selectivity, and why neither is approved for human use.
SLU-PP-915 and SLU-PP-332 are both experimental estrogen-related receptor (ERR) agonists developed in the same Saint Louis University research program, and the key difference between them is generational. SLU-PP-332 is the original first-generation compound, while SLU-PP-915 is a newer analog engineered to improve on its potency and drug-like behavior. Neither compound is FDA-approved, and no human clinical trial results have been published for either one.
What SLU-PP-915 and SLU-PP-332 Actually Are
Both molecules are synthetic ligands that activate the ERR family of nuclear receptors: ERR alpha, ERR beta, and ERR gamma. Because those receptors help regulate mitochondrial function and oxidative metabolism in skeletal muscle, the research literature often describes these compounds as exercise mimetics.
What that means in practical terms:
- They activate gene programs that overlap with some adaptations seen after endurance training.
- In mice, SLU-PP-332 has been reported to increase running endurance and shift muscle metabolism toward greater fat oxidation.
- SLU-PP-915 was developed later, using structural lessons from the first compound, with the goal of better potency and more favorable pharmacokinetics.
Both are small synthetic molecules rather than peptides, even though vendors frequently market them alongside research peptides. Both are sold online as research chemicals intended for laboratory study only.
SLU-PP-915 vs SLU-PP-332: Side-by-Side Comparison
| Feature | SLU-PP-332 | SLU-PP-915 |
|---|---|---|
| Compound class | Synthetic pan-ERR agonist (alpha, beta, gamma) | Second-generation ERR agonist from the same research program |
| Research stage | Preclinical only (cell assays and rodent studies) | Preclinical only (cell assays and rodent studies) |
| Human trials | None completed or registered | None completed or registered |
| FDA approval | None | None |
| Reported profile | Orally active in mice; improved endurance and metabolic gene activation in rodent work | Designed for higher potency and better drug-like properties; much smaller public dataset |
| Known limitations | Limited oral bioavailability, rapid metabolism, activity across all three ERR subtypes | Little long-term or comparative data published to date |
| Availability | Widely sold as a research chemical | Fewer suppliers; typically higher cost per gram |
The most important practical difference is the size of the evidence base. SLU-PP-332 appears in multiple independent preclinical publications, while SLU-PP-915 has a far shorter track record.
Why Researchers Built a Second-Generation ERR Agonist
First-generation drug candidates almost always have flaws, and SLU-PP-332 is no exception. Published work describes limited oral bioavailability, relatively fast metabolic clearance, and activity across all three ERR subtypes, a combination that makes it useful as a laboratory tool but difficult to develop as a therapy.
Second-generation molecules such as SLU-PP-915 are typically engineered to address those problems by:
- Increasing potency so less compound is required for the same receptor activation.
- Improving metabolic stability and oral absorption.
- Tuning receptor selectivity to reduce off-target activity.
This is a normal medicinal chemistry cycle, not proof of superiority. Any advantages SLU-PP-915 shows so far are early-stage and laboratory-based.
What the Preclinical Evidence Shows and What It Does Not
Rodent data on SLU-PP-332 is genuinely notable. Treated mice showed improved endurance capacity and metabolic gene activation without a training program, which is why interest in slu-pp-332 benefits has grown faster than the human evidence supporting them.
What the evidence does not show:
- No completed human trials for either compound.
- No long-term toxicity data in any species beyond short rodent studies.
- No validated method for translating mouse doses to people.
- No head-to-head comparison of SLU-PP-915 and SLU-PP-332 in humans.
People comparing slu-pp-332 vs 5-amino-1mq should note that the two act through completely different pathways, since 5-amino-1mq targets NNMT while SLU-PP-332 targets the ERR receptors. Similar compounds are often discussed together simply because they appear in the same online marketplaces.
Dosing and Safety: The Human Data Gap
There is no established human dose of SLU-PP-915 or SLU-PP-332. Published mouse protocols for SLU-PP-332 have used doses measured in tens of milligrams per kilogram of body weight, given orally or by injection, but body-weight scaling from rodents to humans is unreliable for compounds with unknown human metabolism.
Most third-party discussion of slu-pp-332 dosage traces back to animal protocols or anecdotal self-reports rather than controlled human data. The same gap applies to slu-pp-332 oral vs injection, where the only available pharmacokinetic comparisons come from rodent studies.
Because no human trials have been completed, slu-pp-332 side effects are essentially uncharacterized in people. Anyone with health questions about these compounds should discuss them with a licensed healthcare professional rather than relying on forum posts or vendor marketing.
The Bottom Line
SLU-PP-915 is a second-generation ERR agonist designed to improve on SLU-PP-332's potency and pharmacokinetic profile. Neither SLU-PP-915 nor SLU-PP-332 is FDA-approved for human use in the United States, and neither has been tested in a completed human trial. SLU-PP-332 currently has the larger published dataset, while SLU-PP-915 has the more attractive early-stage drug profile on paper.
For anyone deciding between the two today, the honest answer is that no human evidence base exists for either compound. These remain laboratory tools, and the gap between promising mouse data and proven human outcomes is wide.
Frequently Asked Questions
Is SLU-PP-915 stronger than SLU-PP-332?
In early preclinical assays, SLU-PP-915 is generally described as the more potent of the two, and it was designed specifically to improve on SLU-PP-332's drug-like properties. Potency in a laboratory assay does not predict what a compound will do in humans. There is no head-to-head human data comparing the two compounds.
Are SLU-PP-332 and SLU-PP-915 FDA approved?
No. Neither compound is FDA-approved for human use, and neither can legally be sold as a dietary supplement in the United States. Both are sold as research chemicals intended strictly for laboratory study. Any vendor marketing them as supplements or treatments is making claims that have not gone through regulatory review or clinical testing.
Can you stack SLU-PP-915 with SLU-PP-332?
There is no published data on combining these two compounds in humans or in animals, so any stacking protocol would be entirely experimental. Because both target the same ERR receptors, combining them offers no clear mechanistic advantage. Anyone with health questions about these compounds should consult a licensed healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.